Macrolide antibiotics, bacterial populations and inflammatory airway disease

Netherlands Journal of Medicine

Volumn 61, Issue 7, 2003, Pages 242-248

  Swords, W E ^a   Rubin, B K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; AZITHROMYCIN; CEPHALOSPORIN; CLARITHROMYCIN; ERYTHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROLIDE; PENICILLIN G; PLACEBO; ROXITHROMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BACTERIUM COLONY; BIOFILM; BRONCHIOLITIS; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOMODULATION; MORBIDITY; MORTALITY; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIGNAL TRANSDUCTION; SINUSITIS; TRANSCRIPTION INITIATION; TRANSLATION REGULATION; VIRUS INFECTION; BACTERIUM; DRUG EFFECT; LUNG DISEASE; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIA; BRONCHIOLITIS; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; MACROLIDES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SINUSITIS;

EID: 0242335697     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Woolcock AJ. Epidemiology of chronic airways disease. Chest 1989;96:302-6.
2. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001;14:336-63.
3. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:1067-83.
4. Murphy TF. Haemophilus influenzae in chronic bronchitis. Semin Respir Infect 2000;15:41-51.
5. Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doern GV. Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis 1999;180:404-9.
6. Bresser P, Alphen L van, Habets FJ, et al. Persisting Haemophilus influenzae strains induce lower levels of interleukin-6 and interleukin-8 in H292 lung epithelial cells than nonpersisting strains. Eur Respir J 1997;10:2319-26.
7. Murphy TF, Sethi S, Niederman MS. The role of bacteria in exacerbations of COPD. A constructive view. Chest 2000;118:204-9.
8. Sethi S, Muscarella, K, Evans N, Klingman KL, Grant BJ, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000;118:1557-65.
9. Jacobsen SK, Weis N, Almdal T. Use of antibiotics in patients admitted to the hospital due to acute exacerbation of chronic obstructive pulmonary disease (COPD). Eur J Intern Med 2002;13:514-7.
10. Chinali G, Nyssen E, Di Giambattista M, Cocito C. Inhibition of polypeptide synthesis in cell-free systems by virginiamycin S and erythromycin. Evidence for a common mode of action of type B synergimycins and 14-membered macrolides. Biochim Biophys Acta 1988;949:71-8.
11. Shimane T, Asano K, Suzuki M, Hisamitsu T, Suzaki H. Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro. Mediators Inflamm 2001;10:323-32.
12. Zalewska-Kaszubska J, Gorska D. Anti-inflammatory capabilities of macrolides. Pharmacol Res 2001;44:451-4.
13. Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001;205:1-7.
14. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-73.
15. Rubin BK, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs 2000;1:169-72.
16. Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001;13:3-8.
17. Inamura K, Ohta N, Fukase S, Kasajima N, Aoyagi M. The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 2000;38:124-9.
18. Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000;267:124-8.
19. Abe S, Nakamura H, Inoue S, et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;22:51-60.
20. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001;429:209-29.
21. Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002;49:745-55.
22. Ichiyama T, Nishikawa M, Yoshitomi T, et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001;45:44-7.
23. Nagaya T, Fujieda M, Otsuka G, Yang JP, Okamoto T, Seo H. A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome. J Clin Invest 2000;106:393-402.
24. Dezaki S, Takizawa H, Morita K, Yamamoto K. Effects of macrolides on several transcription factors. Jpn J Antibiot 2000;53(suppl A):93-4.
25. Miyanohara T, Ushikai M, Matsune S, Ueno K, Katahira S, Kurono Y. Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. Laryngoscope 2000;110:126-31.
26. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990;141:72-8.
27. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-94.
28. Society AT. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
29. National Heart Lung, and Blood Institute. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, Md: National Institutes of Health, 1998.
30. Vollmer WM, Osborne ML, Buist AS. 20-year trends in the prevalence of asthma and chronic airflow obstruction in an HMO. Am J Respir Crit Care Med 1998;157(4 pt 1):1079-84.
31. Gulsvik A. The global burden and impact of chronic obstructive pulmonary disease worldwide. Monaldi Arch Chest Dis 2001;56:261-4.
32. Ward SA, Casaburi R. 21st century perspective on chronic obstructive pulmonary disease. Respiration 2001;68:557-61.
33. Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am J Med 2001;111:S4-12.
34. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
35. Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990;142:1004-8.
36. Hirschmann JV. Bacteria and COPD exacerbations redux. Chest 2001;119:663-7.
37. Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest 2000;118:193-203.
38. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
39. Vitovski S, Dunkin KT, Howard AJ, Sayers JR. Nontypeable Haemophilus influenzae in carriage and disease: a difference in IgA1 protease activity levels. JAMA 2002;287:1699-705.
40. Murphy TF, Sethi S. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient. Drugs Aging 2002;19:761-75.
41. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest 2001;120:730-3.
42. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997;10:994-9.
43. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999;13:361-4.
44. Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999;13:1371-9.
45. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002;15:194-222.
46. Gill JF, Deretic V, Chakrabarty AM. Alginate production by the mucoid Pseudomonas aeruginosa associated with cystic fibrosis. Microbiol Sci 1987;4:296-9.
47. Hentzer M, Teitzel GM, Balzer GJ, et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 2001;183:5395-401.
48. Schaefer AL, Greenberg EP, Parsek MR. Acylated homoserine lactone detection in Pseudomonas aeruginosa biofilms by radiolabel assay. Methods Enzymol 2001;336:41-7.
49. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-4.
50. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998;280:295-8.
51. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-36. [published erratum appears in Cell 1996;87(2):355]
52. Pier GB. Peptides, Pseudomonas aeruginosa, polysaccharides and lipopolysaccharides-players in the predicament of cystic fibrosis patients. Trends Microbiol 2000;8:247-50.
53. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 1997;94:12088-93.
54. Zaidi TS, Lyczak J, Preston M, Pier GB. Cystic fibrosis transmembrane conductance regulator-mediated corneal epithelial cell ingestion of Pseudomonas aeruginosa is a key component in the pathogenesis of experimental murine keratitis. Infect Immun 1999;67:1481-92.
55. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A 2000;97:8822-8.
56. Carnoy C, Ramphal R, Scharfman A, et al. Altered carbohydrate composition of salivary mucins from patients with cystic fibrosis and the adhesion of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol 1993;9:323-34.
57. Ramphal R, Pyle M. Evidence for mucins and sialic acid as receptors for Pseudomonas aeruginosa in the lower respiratory tract. Infect Immun 1983;41:339-44.
58. Ramphal R, Pyle M. Adherence of mucoid and nonmucoid Pseudomonas aeruginosa to acid-injured tracheal epithelium. Infect Immun 1983;41:345-51.
59. Vishwanath S, Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun 1984;45:197-202.
60. Vishwanath S, Ramphal R. Tracheobronchial mucin receptor for Pseudomonas aeruginosa: predominance of amino sugars in binding sites. Infect Immun 1985;48:331-5.
61. Ramphal R. Molecular basis of mucin-Pseudomonas interactions. Biochem Soc Trans 1999;27:474-7.
62. Ramphal R, Arora SK. Recognition of mucin components by Pseudomonas aeruginosa. Glycoconj J 2001;18:709-13.
63. Du M, Jones JR, Lanier J, et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med 2002;80:595-604.
64. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001;163:1683-92.
65. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 2000;6:1044-55.
66. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997;3:1280-4.
67. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996;2:467-9.
68. Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 1997;40:153-5.
69. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84.
70. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
71. Ordonez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001;32:29-37.
72. Wolter JM, McCormack JG. The effect of subinhibitory concentrations of antibiotics on adherence of Pseudomonas aeruginosa to cystic fibrosis (CF) and non-CF-affected tracheal epithelial cells. J Infect 1998;37:217-23.
73. Kita E, Sawaki M, Oku D, Hamuro A, et al. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 1991;27:273-84.
74. Vranes J. Effect of subminimal inhibitory concentrations of azithromycin on adherence of Pseudomonas aeruginosa to polystyrene. J Chemother 2000;12:280-5.
75. Dupont MJ, Lapointe JR. Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin. J Antimicrob Chemother 1995;36:231-6.
76. Doring G. Cystic fibrosis respiratory infections: interactions between bacteria and host defence. Monaldi Arch Chest Dis 1997;52:363-6.
77. Garey KW, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 2003;123:261-5.
78. Finegold SM, Flynn MJ, Rose FV, et al. Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults. Clin Infect Dis 2002;35:428-33.
79. Rubin LG, St Geme JW 3rd. Role of lipooligosaccharide in virulence of the Brazilian purpuric fever clone of Haemophilus influenzae biogroup aegyptius for infant rats. Infect Immun 1993;61:650-5.
80. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000;14:143-8.
81. Abe M, Hashimoto S, Hara H. A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist. Respir Med 1998;92:1084-6.
82. Takahashi T, Suga M, Matsukawa A, et al. Erythromycin attenuates an experimental model of chronic bronchiolitis via augmenting monocyte chemoattractant protein-1. Eur Respir J 2001;17:360-7.
83. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med 1998;4:116-21.
84. Ichimiya T, Yamasaki T, Nasu M. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J Antimicrob Chemother 1994;34:331-41.
85. Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 1993;37:1749-55.
86. Kondoh K, Hashiba M, Baba S. Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Acta Otolaryngol Suppl 1996;525:56-60.
87. Ozeki M, Miyamoto N, Hashiba M, Baba S. Inhibitory effect of roxithromycin on biofilm formation of Pseudomonas aeruginosa. Acta Otolaryngol Suppl 1996;525:61-3.
88. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996;42:186-91.
89. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002;295:1487.
90. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;84:594-8.
91. Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 1994;105:308-16.
92. Shimizu T, Kato M, Mochizuki H, et al. Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma. J Asthma 1997;34:211-7.
93. Shimizu T, Kato M, Mochizuki H, Tokuyama K, Morikawa A, Kuroume T. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 1994;106:458-61.
94. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-4.
95. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002;417:552-5.